ANTARES PHARMA INC (ATRS) Stock Price, Quote, News and Overview
NASDAQ:ATRS - Nasdaq - US0366421065 - Common Stock
ATRS Quote, Performance and Key Statistics
5.59
0 (0%)
The current stock price of ATRS is 5.59 null. In the past month the price increased by 0.54%. In the past year, price increased by 40.81%.
ATRS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ATRS
Company Profile
Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. The company is headquartered in Ewing, New Jersey and currently employs 201 full-time employees. The firm is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The firm develops, manufactures, and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. The firm products include XYOSTED (testosterone enanthate) injection, NOCDURNA (desmopressin acetate), OTREXUP (methotrexate) injection, Epinephrine Injection USP, Sumatriptan Injection USP, Makena Subcutaneous Auto Injector and Teriparatide Injection. Its testosterone enanthate injection product is indicated for testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Its desmopressin acetate is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate.
Company Info
ANTARES PHARMA INC
100 Princeton South, Suite 300
Ewing NEW JERSEY 08628 US
CEO: Robert F. Apple
Employees: 201
Company Website: https://www.antarespharma.com/
Phone: 16093593020.0
ANTARES PHARMA INC / ATRS FAQ
What is the stock price of ANTARES PHARMA INC today?
The current stock price of ATRS is 5.59 null.
What is the ticker symbol for ANTARES PHARMA INC stock?
The exchange symbol of ANTARES PHARMA INC is ATRS and it is listed on the Nasdaq exchange.
On which exchange is ATRS stock listed?
ATRS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ANTARES PHARMA INC stock?
12 analysts have analysed ATRS and the average price target is 6.07 null. This implies a price increase of 8.57% is expected in the next year compared to the current price of 5.59. Check the ANTARES PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ANTARES PHARMA INC worth?
ANTARES PHARMA INC (ATRS) has a market capitalization of 955.06M null. This makes ATRS a Small Cap stock.
How many employees does ANTARES PHARMA INC have?
ANTARES PHARMA INC (ATRS) currently has 201 employees.
What are the support and resistance levels for ANTARES PHARMA INC (ATRS) stock?
ANTARES PHARMA INC (ATRS) has a support level at 5.58 and a resistance level at 5.6. Check the full technical report for a detailed analysis of ATRS support and resistance levels.
Is ANTARES PHARMA INC (ATRS) expected to grow?
The Revenue of ANTARES PHARMA INC (ATRS) is expected to grow by 15.42% in the next year. Check the estimates tab for more information on the ATRS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ANTARES PHARMA INC (ATRS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATRS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATRS, evaluating the profitability, health, valuation and growth aspects
- ANTARES PHARMA INC (ATRS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ANTARES PHARMA INC (ATRS) Sales and EPS estimates to see what analysts future expectations are.
- ANTARES PHARMA INC (ATRS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ANTARES PHARMA INC (ATRS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ANTARES PHARMA INC (ATRS) Stock Chart to make your own analysis
- ANTARES PHARMA INC (ATRS) Latest news and press-releases to stay up to date.
Does ANTARES PHARMA INC (ATRS) stock pay dividends?
ATRS does not pay a dividend.
When does ANTARES PHARMA INC (ATRS) report earnings?
ANTARES PHARMA INC (ATRS) will report earnings on 2022-08-03.
What is the Price/Earnings (PE) ratio of ANTARES PHARMA INC (ATRS)?
The PE ratio for ANTARES PHARMA INC (ATRS) is 20.7. This is based on the reported non-GAAP earnings per share of 0.27 and the current share price of 5.59 null. Check the full fundamental report for a full analysis of the valuation metrics for ATRS.
ATRS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ATRS. When comparing the yearly performance of all stocks, ATRS is one of the better performing stocks in the market, outperforming 98.01% of all stocks.
ATRS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ATRS. ATRS has only an average score on both its financial health and profitability.
ATRS Financial Highlights
Over the last trailing twelve months ATRS reported a non-GAAP Earnings per Share(EPS) of 0.27. The EPS increased by 350% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.15% | ||
| ROA | 17.97% | ||
| ROE | 26.33% | ||
| Debt/Equity | 0.1 |
ATRS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to ATRS. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -69.78% and a revenue growth 15.42% for ATRS